on NanoViricides, Inc. (NASDAQ:NNVC)
NanoViricides to Showcase Revolutionary Antiviral Drug at LSX Congress
NanoViricides, Inc., a clinical-stage developer of antiviral drugs, is set to present at the LSX World Congress 2025 in Boston on September 17th. The presentation by Dr. Anil R. Diwan, President and Executive Chairman, will update participants on the company's drug pipeline, including NV-387, an advanced broad-spectrum antiviral candidate.
NV-387 targets respiratory viruses and is touted as a breakthrough comparable to antibiotics' impact on bacterial infections. The drug disrupts virus particles, preventing infection and overcoming virus evolution challenges seen with vaccines and small molecules.
Additionally, NV-387 is advancing towards a Phase II evaluation for MPOX treatment. NanoViricides is also developing NV-HHV-1, an anti-herpesvirus drug, and NV-HIV-1 for HIV.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NanoViricides, Inc. news